Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
acknowledged, adult, Advice, adware, aimed, analyzed, antitumor, argued, ascending, Basel, BCC, biopsy, bundled, CCPA, Chromatography, CMO, condensed, constraint, corroborated, CPRA, credential, crush, distinct, Economy, EEA, EGW, EOS, EOT, EU, explicitly, exploratory, Gas, Gay, GDPR, hardware, herewith, histological, imputed, incarceration, interface, intratumorally, ITT, Jr, Kingdom, Kohler, licensee, misuse, nonrefundable, offline, oIf, online, oOur, oThe, PCT, pertinent, phishing, PK, presidential, ransomware, recognition, rescinded, Rescue, sequester, server, shipped, Spectrometry, stringent, stuffing, suggesting, SVB, Terence, text, theft, threat, traditional, turnover, UK, unconditional, VAI, vehicle, Virginia, warranted, whichever, workforce
Filing tables
Filing exhibits
Related press release
VRCA similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Verrica Pharmaceuticals Inc.:
We consent to the incorporation by reference in the registration statements (Nos. 333-226153, 333-231265, 333-237174, and 333-255919) on Form S-8 and (No. 333-237171) on Form S-3 of Verrica Pharmaceuticals Inc. of our report dated March 2, 2022, with respect to financial statements of Verrica Pharmaceuticals Inc.
/s/ KPMG LLP
Philadelphia, Pennsylvania
March 2, 2022